Artificial Intelligence has suddenly gone from the fringes of science to being everywhere. So how did we get here? And where's this all heading? In this new series of Science Friction, we're finding out.
…
continue reading
Indhold leveret af UpToDate Talk. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af UpToDate Talk eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
Naltrexone versus buprenorphine for opioid use disorder
MP3•Episode hjem
Manage episode 201213843 series 107329
Indhold leveret af UpToDate Talk. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af UpToDate Talk eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts. Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association's Council on Addiction Psychiatry. References: Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197. Contributor Disclosure: Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].
…
continue reading
58 episoder
MP3•Episode hjem
Manage episode 201213843 series 107329
Indhold leveret af UpToDate Talk. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af UpToDate Talk eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
This episode features Dr. Andrew Saxon discussing treatments for opioid use disorder. Dr. Jennifer Mitty hosts. Dr. Saxon is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington in Seattle, and he is Chair of the American Psychiatric Association's Council on Addiction Psychiatry. References: Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 2018; 391:309. Tanum L, Solli KK, Latif ZE, et al. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial. JAMA Psychiatry 2017; 74:1197. Contributor Disclosure: Grant/Research/Clinical Trial Support: Medicasafe [Medication dispensing]. Consultant/Advisory Boards: Neurocrine Biosciences [Tardive dyskinesia (Valbenazine)].
…
continue reading
58 episoder
Όλα τα επεισόδια
×Velkommen til Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.